

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to editors]

1. About E2609

Discovered in-house by Eisai, E2609 is an investigational next-generation oral candidate for the treatment of Alzheimer's disease that is believed to inhibit beta Eisai